{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:03Z","timestamp":1794047403696,"version":"4.8.0"},"reference-count":13,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2021.280284","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T03:36:12Z","timestamp":1640835372000},"page":"1500-1502","source":"Crossref","is-referenced-by-count":0,"title":["Did brentuximab vedotin\u2019s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?"],"prefix":"10.3324","volume":"107","author":[{"given":"Mehdi","family":"Hamadani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"37170","doi-asserted-by":"crossref","unstructured":"Linch DC, Winfield D, Goldstone AH. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993; 341(8852):1051-1054.","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"37171","doi-asserted-by":"crossref","unstructured":"Schmitz N, Pfistner B, Sextro M. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002; 359(9323):2065-2071.","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"37172","doi-asserted-by":"crossref","unstructured":"Satwani P, Ahn KW, Carreras J. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015; 50(11):1416-1423.","DOI":"10.1038\/bmt.2015.177"},{"key":"37173","doi-asserted-by":"crossref","unstructured":"Doronina SO, Toki BE, Torgov MY. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003; 21(7):778-784.","DOI":"10.1038\/nbt832"},{"key":"37174","doi-asserted-by":"crossref","unstructured":"Younes A, Gopal AK, Smith SE. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30(18):2183-2189.","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"37175","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Nademanee A, Masszi T. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 385(9980):1853-1862.","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"37176","doi-asserted-by":"crossref","unstructured":"Connors JM, Jurczak W, Straus DJ. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2017; 378(4):331-344.","DOI":"10.1056\/NEJMoa1708984"},{"key":"37177","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Sch\u00f6der H, Yahalom J. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015; 16(3):284-292.","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"37178","doi-asserted-by":"crossref","unstructured":"Kanate AS, Kumar A, Dreger P. Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019; 5(5):715-722.","DOI":"10.1001\/jamaoncol.2018.6278"},{"key":"37179","doi-asserted-by":"crossref","unstructured":"Marouf A, Cottereau AS, Kanoun S. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study. Haematologica. 2022; 107(7):1685-1690.","DOI":"10.3324\/haematol.2021.279564"},{"key":"37180","unstructured":"Publisher Full Text|"},{"key":"37181","doi-asserted-by":"crossref","unstructured":"Armand P, Chen Y-B, Redd RA. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019; 134(1):22-29.","DOI":"10.1182\/blood.2019000215"},{"key":"37182","doi-asserted-by":"crossref","unstructured":"Kuruvilla J, Ramchandren R, Santoro A. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021; 22(4):512-524.","DOI":"10.1016\/S1470-2045(21)00005-X"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280284\/74040","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280284\/74570","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10491\/74040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:49Z","timestamp":1794045649000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.280284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,30]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.280284","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,30]]}}}